(-0.10%) 5 464.00 points
(-0.09%) 39 076 points
(0.15%) 17 744 points
(-0.74%) $80.23
(-4.32%) $2.64
(-0.84%) $2 311.30
(0.01%) $28.87
(2.32%) $1 009.30
(0.30%) $0.936
(0.73%) $10.68
(0.49%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders...
Stats | |
---|---|
Today's Volume | 170 627 |
Average Volume | 0 |
Market Cap | 40.85M |
EPS | $-0.310 ( Q3 | 2022-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.684 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.104 (10.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-02-10 | Aberman Zami | Buy | 80 616 | Common Stock |
2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 122 663 | Common Stock |
2021-05-26 | Clover Wolf Capital - Limited Partnership | Sell | 22 015 | Common Stock |
2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 71 775 | Common stock |
2021-05-27 | Clover Wolf Capital - Limited Partnership | Sell | 24 110 | Common stock |
INSIDER POWER |
---|
0.00 |
Last 98 transactions |
Buy: 11 245 290 | Sell: 1 084 851 |
Volume Correlation
Pluristem Therapeutics Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pluristem Therapeutics Correlation - Currency/Commodity
Pluristem Therapeutics Financials
Annual | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.770 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.770 |
FY | 2020 |
Revenue: | $23 000.00 |
Gross Profit: | $23 000.00 (100.00 %) |
EPS: | $-1.600 |
FY | 2019 |
Revenue: | $54 000.00 |
Gross Profit: | $52 000.00 (96.30 %) |
EPS: | $-2.90 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Pluristem Therapeutics
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA\'s Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators